Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) CMO David Shapiro unloaded 5,036 shares of the company’s stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $244.73, for a total transaction of $1,232,460.28. Following the sale, the chief marketing officer now directly owns 15,027 shares in the company, valued at approximately $3,677,558. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Goldman Sachs initiated coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday. They set a “neutral” rating and a $265.00 price target on the stock. Separately, analysts at RBC Capital initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday. They set an “outperform” rating and a $425.00 price target on the stock. Finally, analysts at Summer Street reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Friday, June 27th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $457.56.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 0.50% during mid-day trading on Thursday, hitting $244.98. The stock had a trading volume of 171,897 shares. Intercept Pharmaceuticals has a 52-week low of $42.41 and a 52-week high of $497.00. The stock has a 50-day moving average of $257.2 and a 200-day moving average of $279.8. The company’s market cap is $5.166 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings data on Wednesday, May 7th. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.87. Analysts expect that Intercept Pharmaceuticals will post $-14.92 EPS for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.